Founded in 2013, NantOmics operates in biotechnology / molecular diagnostics. Investors last valued the company at $100M. Its shares do not trade on a public exchange.
One company valuation: $100M, dated May 2022.
NantOmics develops molecular diagnostic and genomic sequencing products for personalized cancer treatment, including its GPS Cancer platform, which sequences the genome and RNA of tumor cells against normal cells from the same patient to guide individualized therapy. The company built up its portfolio through acquisitions, buying cancer diagnostics company OncoPlex Dx in 2015 and consumer genomics startup Genos in 2017, later shutting Genos down in 2020.
Its customers are oncologists and cancer patients seeking molecular profiling to inform treatment decisions, with a 2017 pilot project involving about 327,000 cancer patients. NantOmics was founded in 2013 by Patrick Soon-Shiong and is based in Culver City, California, as part of his NantWorks network of biotech companies. A notable fact: NantOmics operates a highly scalable cloud infrastructure capable of processing thousands of genomes a day.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds NantOmics.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. NantOmics availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — NantOmics included.
No. NantOmics is a private company; its shares do not trade on a public exchange.
The last valuation is $100M.
Lead investors for each round are in the funding timeline.
The closest biotechnology / molecular diagnostics peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
